Predicted protein targets (top 3)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.34 |
| ▸ | MCOLN3 | Q8TDD5 | 1/20 | 0.33 |
| ▸ | MMP13 | P45452 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30939527 | 1.00 | KDM4E (0.34) | KDM4EMCOLN3MMP13 | |
| SCHEMBL18053270 | 0.90 | — | — | |
| SCHEMBL30939617 | 0.89 | AR (0.39) | KDM4EMCOLN3MMP13 | |
| SCHEMBL9924307 | 0.89 | AR (0.39) | KDM4EMCOLN3MMP13 | |
| SCHEMBL30939564 | 0.86 | MMP13 (0.32) | KDM4EMCOLN3MMP13 | |
| SCHEMBL9923854 | 0.86 | MMP13 (0.32) | KDM4EMCOLN3MMP13 | |
| SCHEMBL9904969 | 0.86 | KDM4E (0.35) | KDM4EMCOLN3MMP13 | |
| SCHEMBL15303437 | 0.86 | KDM4E (0.35) | KDM4EMCOLN3MMP13 | |
| SCHEMBL30939625 | 0.86 | KDM4E (0.35) | KDM4EMCOLN3MMP13 | |
| SCHEMBL29437964 | 0.86 | KDM4E (0.35) | KDM4EMCOLN3MMP13 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 38 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2649066-B1 | HYDANTOIN DERIVATIVES USEFUL AS KV3 INHIBITORS | AUTIFONY THERAPEUTICS LTD (GB) | 2015-10-21 | — | — | EP | claimed |
| US-20250017925-A1 | MODULATORS OF KV3 CHANNELS TO TREAT PAIN | AUTIFONY THERAPEUTICS LIMITED (GB) | 2025-01-16 | — | — | US | disclosed |
| CN-118267386-A | Modulators of KV3 channels for the treatment of pain | 奥提芙尼治疗学有限公司 | 2024-07-02 | — | — | CN | disclosed |
| CN-108472288-B | Modulators of KV3 channels for the treatment of pain | 奥提芙尼治疗学有限公司 | 2024-05-28 | — | — | CN | disclosed |
| US-11944623-B2 | Modulators of Kv3 channels to treat pain | AUTIFONY THERAPEUTICS LIMITED (GB) | 2024-04-02 | — | — | US | disclosed |
| EP-3386506-B1 | MODULATORS OF KV3 CHANNELS TO TREAT PAIN | AUTIFONY THERAPEUTICS LTD (GB) | 2024-01-24 | — | — | EP | disclosed |
| US-11583527-B2 | Hydantoin derivatives useful as Kv3 inhibitors | AUTIFONY THERAPEUTICS LIMITED (GB) | 2023-02-21 | — | — | US | disclosed |
| US-11583527-B2 | Hydantoin derivatives useful as Kv3 inhibitors | AUTIFONY THERAPEUTICS LIMITED (GB) | 2023-02-21 | — | — | US | disclosed |
| US-20220071998-A1 | MODULATORS OF KV3 CHANNELS TO TREAT PAIN | AUTIFONY THERAPEUTICS LIMITED (GB) | 2022-03-10 | — | — | US | disclosed |
| US-20220054490-A1 | HYDANTOIN DERIVATIVES USEFUL AS KV3 INHIBITORS | AUTIFONY THERAPEUTICS LIMITED (GB) | 2022-02-24 | — | — | US | disclosed |
| US-20160251340-A1 | HYDANTOIN DERIVATIVES USEFUL AS KV3 INHIBITORS | GLAXOSMITHKLINE S.P.A. (IT) | 2016-09-01 | — | — | US | disclosed |
| US-9346790-B2 | Hydantoin derivatives useful as Kv3 inhibitors | AUTIFONY THERAPEUTICS LIMITED (GB) | 2016-05-24 | — | — | US | disclosed |
| US-9346790-B2 | Hydantoin derivatives useful as Kv3 inhibitors | AUTIFONY THERAPEUTICS LIMITED (GB) | 2016-05-24 | — | — | US | disclosed |
| US-9346790-B2 | Hydantoin derivatives useful as Kv3 inhibitors | AUTIFONY THERAPEUTICS LIMITED (GB) | 2016-05-24 | — | — | US | disclosed |
| EP-2649066-B1 | HYDANTOIN DERIVATIVES USEFUL AS KV3 INHIBITORS | AUTIFONY THERAPEUTICS LTD (GB) | 2015-10-21 | — | — | EP | disclosed |
| US-20150157631-A1 | HYDANTOIN DERIVATIVES AS KV3 INHIBITORS | AUTIFONY THERAPEUTICS LIMITED (GB) | 2015-06-11 | — | — | US | disclosed |
| US-20130267510-A1 | HYDANTOIN DERIVATIVES USEFUL AS KV3 INHIBITORS | AUTIFONY THERAPEUTICS LIMITED (GB) | 2013-10-10 | — | — | US | disclosed |
| US-20130267510-A1 | HYDANTOIN DERIVATIVES USEFUL AS KV3 INHIBITORS | AUTIFONY THERAPEUTICS LIMITED (GB) | 2013-10-10 | — | — | US | disclosed |
| US-20130267510-A1 | HYDANTOIN DERIVATIVES USEFUL AS KV3 INHIBITORS | AUTIFONY THERAPEUTICS LIMITED (GB) | 2013-10-10 | — | — | US | disclosed |
| WO-2012076877-A1 | HYDANTOIN DERIVATIVES USEFUL AS KV3 INHIBITORS | AUTIFONY THERAPEUTICS LIMITED (GB) | 2012-06-14 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (8 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20160251340-A1 | HYDANTOIN DERIVATIVES USEFUL AS KV3 INHIBITORS | KCNA3, KCND3, KCNN3 | KDM4E 958/4885MCOLN3 324/4885MMP13 3274/4885 |
| US-11583527-B2 | Hydantoin derivatives useful as Kv3 inhibitors | KCNN3, KCND3, KCNA3 | KDM4E 1460/4885MCOLN3 288/4885MMP13 3782/4885 |
| US-20220054490-A1 | HYDANTOIN DERIVATIVES USEFUL AS KV3 INHIBITORS | KCNN3, KCND3, KCNA3 | KDM4E 1460/4885MCOLN3 288/4885MMP13 3782/4885 |
| US-11944623-B2 | Modulators of Kv3 channels to treat pain | KCNN3, KCNA3, KCND3 | KDM4E 871/4885MCOLN3 166/4885MMP13 1693/4885 |
| US-20150157631-A1 | HYDANTOIN DERIVATIVES AS KV3 INHIBITORS | KCND3, KCNA3, KCNK3 | KDM4E 674/4885MCOLN3 1478/4885MMP13 1968/4885 |
| US-20220071998-A1 | MODULATORS OF KV3 CHANNELS TO TREAT PAIN | KCNN3, KCNA3, KCND3 | KDM4E 871/4885MCOLN3 166/4885MMP13 1693/4885 |
| US-20130267510-A1 | HYDANTOIN DERIVATIVES USEFUL AS KV3 INHIBITORS | KCNA3, KCND3, KCNN3 | KDM4E 958/4885MCOLN3 324/4885MMP13 3274/4885 |
| US-20250017925-A1 | MODULATORS OF KV3 CHANNELS TO TREAT PAIN | KCNN3, KCNA3, KCND3 | KDM4E 871/4885MCOLN3 166/4885MMP13 1693/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.